COCP Cocrystal Pharma Inc.

2.51
-0.19  -7%
Previous Close 2.7
Open 2.63
Price To Book 1.18
Market Cap 79367821
Shares 31,620,646
Volume 15,444
Short Ratio
Av. Daily Volume 8,222

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a initial data released January 22, 2019. SVR12 66%.
CC-31244
Hepatitis C
Phase 1 trial to be initiated in 2019.
CC-42344
Influenza

Latest News

  1. Cocrystal Pharma Reports 2018 Financial Results and Provides Corporate Overview and Business Outlook
  2. Cocrystal Pharma Announces Closing of Private Placement
  3. Cocrystal Pharma Provides Update on Clinical Development Program Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
  4. Robbins Arroyo LLP: Shareholder Lawsuit Says Cocrystal Pharma, Inc. (COCP) Misled Shareholders
  5. Cocrystal Announces Board Changes
  6. 4 Pharma Stocks Raising Eyebrows (1/3/19)
  7. Cocrystal Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck
  8. Cocrystal Pharma Announces Presentation at the RespiDART 2018: Frontiers in Drug Development Against Respiratory Viruses Conference
  9. WeissLaw LLP: Cocrystal Pharma, Inc. is the Subject of a Legal Investigation
  10. DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cocrystal Pharma, Inc. (Formerly BioZone Pharmaceuticals, Inc.) and Encourages Investors with Losses of $100,000 to Contact the Firm
  11. FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Cocrystal Pharma, Inc. f/k/a/ BioZone Pharmaceuticals, Inc. (COCP) and Lead Plaintiff Deadline – November 19, 2018
  12. Detailed Research: Economic Perspectives on Cocrystal Pharma, Genius Brands International, Gemphire Therapeutics, Global Water Resources, Infrastructure and Energy Alternatives, and Condor Hospitality Trust — What Drives Growth in Today's Competitive Landscape
  13. CLASS ACTION UPDATE for COCP, JT and DY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  14. DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cocrystal Pharma, Inc. (Formerly BioZone Pharmaceuticals, Inc.) and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
  15. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of COCP, ABBV, CHGG, HON and DY
  16. COCP DEADLINE NOTICE ALERT: Rosen Law Firm Reminds Cocrystal Pharma, Inc. Investors of Important Nov. 19 Deadline in First Filed Case – COCP
  17. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Cocrystal Pharma, Inc. To Contact The Firm
  18. DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Cocrystal Pharma, Inc. f/k/a/ BioZone Pharmaceuticals, Inc. (COCP) and Lead Plaintiff Deadline - November 19, 2018